Press releases

The success of the EU’s promising mobility strategy, unveiled today, will depend on legislative follow-up that should make it easier to travel from A to B in a sustainable manner.

Today, the Court of Justice of the EU, although ruling in favour of Groupe Canal+’s appeal on procedural grounds, confirmed that the General Court was right in its assessment of the anti-competitive nature of the clauses in its judgement of 12 December 2018.

The European Consumer Organisation (BEUC) welcomes the European Commission’s decision today to fine Teva and Cephalon 30 and 30.5 million euros respectively for agreeing not to market a cheaper generic version of Cephalon's drug for sleep disorders, modafinil, in Europe for six years. The “pay for delay” agreement, which the Commission has found to violate EU antitrust rules, allowed Cephalon to charge European patients and healthcare systems higher prices for the drug in the six year period before Teva finally marketed its generic alternative.

The EU Commission published its Pharmaceutical Strategy today, aiming to ensure patients timely access to safe and affordable treatment and to support medical innovation and pharma competitiveness. The Strategy brings momentum to effectively address medicine shortages and high prices, a long-standing issue in the EU.